{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:55Z","timestamp":1792114135604,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.06.071","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T04:06:09Z","timestamp":1467950769000},"page":"6597-6609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment"],"prefix":"10.1016","volume":"34","author":[{"given":"David K.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Seligman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Klug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Mac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baevin","family":"Carbery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.071_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14760584.6.2.255","article-title":"Use of viral vectors for the development of vaccines","volume":"6","author":"Liniger","year":"2007","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.06.071_b0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biologicals.2010.03.005","article-title":"Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference","volume":"38","author":"Excler","year":"2010","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.06.071_b0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-3024.2009.01141.x","article-title":"Viral vectors in malaria vaccine development","volume":"31","author":"Limbach","year":"2009","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tube.2006.01.017","article-title":"Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization","volume":"86","author":"Xing","year":"2006","journal-title":"Tuberculosis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0025","article-title":"Applications and challenges of multivalent recombinant vaccines","volume":"9","author":"Naim","year":"2012","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2016.06.071_b0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/COH.0b013e328363d3b7","article-title":"Nonreplicating vectors in HIV vaccines","volume":"8","author":"Johnson","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2016.06.071_b0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COH.0b013e328363d389","article-title":"Development of replication-competent viral vectors for HIV vaccine delivery","volume":"8","author":"Parks","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2016.06.071_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(14)61371-4","article-title":"Experimental Ebola drugs enter the limelight","volume":"384","author":"Mullard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.071_b0050","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.071_b0055","unstructured":"WHO Initiative for Vaccine Research. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors. December 2003."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.06.071_b0060","doi-asserted-by":"crossref","first-page":"B108","DOI":"10.1016\/j.vaccine.2012.10.119","article-title":"Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization","volume":"31","author":"Amarasinghe","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0065","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.biologicals.2011.08.001","article-title":"Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?","volume":"40","author":"MacDonald","year":"2012","journal-title":"Biologicals: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.06.071_b0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3928\/0090-4481-19980701-11","article-title":"Vaccine safety: current and future challenges","volume":"27","author":"Chen","year":"1998","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.vaccine.2016.06.071_b0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.06.071_b0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0085","series-title":"Rhabdoviruses as vaccine vectors: from initial development to clinical trials","author":"John","year":"2015"},{"key":"10.1016\/j.vaccine.2016.06.071_b0090","doi-asserted-by":"crossref","first-page":"ofv082","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0095","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1128\/JVI.77.14.8039-8047.2003","article-title":"Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host","volume":"77","author":"Martinez","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0100","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.06.071_b0105","doi-asserted-by":"crossref","first-page":"9317","DOI":"10.1128\/JVI.78.17.9317-9324.2004","article-title":"Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses","volume":"78","author":"Publicover","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0110","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM196711092771901","article-title":"Human infection with the virus of vesicular stomatitis during an epizootic","volume":"277","author":"Fields","year":"1967","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.071_b0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1966.15.244","article-title":"Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)","volume":"15","author":"Johnson","year":"1966","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2016.06.071_b0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4269\/ajtmh.1976.25.875","article-title":"Ecological associations of vesicular stomatitis virus in rural Central America and Panama","volume":"25","author":"Cline","year":"1976","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2016.06.071_b0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.aje.a121068","article-title":"Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity","volume":"90","author":"Tesh","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0130","unstructured":"Hanson RP, Karstad L. Further studies on enzootic vesicular stomatitis. In: Proc US Livestock Sanit Assoc; 1957."},{"key":"10.1016\/j.vaccine.2016.06.071_b0135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(81)90143-4","article-title":"Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription","volume":"23","author":"Iverson","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.06.071_b0140","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1073\/pnas.95.7.3501","article-title":"Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus","volume":"95","author":"Wertz","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.071_b0145","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/JVI.73.6.4705-4712.1999","article-title":"Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus","volume":"73","author":"Ball","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0150","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1128\/JVI.75.13.6107-6114.2001","article-title":"Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development","volume":"75","author":"Flanagan","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0155","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1128\/JVI.70.4.2318-2323.1996","article-title":"The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus","volume":"70","author":"Schnell","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/viro.1999.0120","article-title":"Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope","volume":"268","author":"Haglund","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.071_b0165","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2012.11.007","article-title":"Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression","volume":"171","author":"An","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2016.06.071_b0170","doi-asserted-by":"crossref","first-page":"12807","DOI":"10.1128\/JVI.77.23.12807-12818.2003","article-title":"The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity","volume":"77","author":"Jeetendra","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0175","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2016.06.071_b0180","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0185","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus","author":"Matassov","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vacc"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2016.06.071_b0195","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0200","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0205","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.071_b0210","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0215","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0220","doi-asserted-by":"crossref","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.06.071_b0225","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/JVI.63.9.3569-3578.1989","article-title":"Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant","volume":"63","author":"Whitt","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector","author":"Clarke","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0235","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.071_b0245","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates","volume":"88","author":"Clarke","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0255","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1128\/JVI.77.8.4646-4657.2003","article-title":"Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis","volume":"77","author":"Ahmed","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0260","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1128\/JVI.79.7.4170-4179.2005","article-title":"Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways","volume":"79","author":"Gaddy","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2016.06.071_b0270","unstructured":"U.S. Food and Drug Administration. 21 CFR 630 - Additional standards for viral vaccines, vol. 21. In: USFDA, editor; 1996."},{"key":"10.1016\/j.vaccine.2016.06.071_b0275","unstructured":"World Health Organization. Standard Operating Procedure: Neurovirulence test of types 1, 2 or 3 live poliomyelitis vaccines (oral) in monkeys; 2012."},{"key":"10.1016\/j.vaccine.2016.06.071_b0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7883\/yoken1952.29.177","article-title":"Growth of measles virus in nervous tissues. IV. Neurovirulence of wild measles and SSPE viruses in monkeys","volume":"29","author":"Yamanouchi","year":"1976","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-1157(79)80033-5","article-title":"On the morphological evaluation of the neurovirulence safety of attenuated mumps virus strains in monkeys","volume":"7","author":"Levenbuk","year":"1979","journal-title":"J Biol Standard"},{"key":"10.1016\/j.vaccine.2016.06.071_b0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-1157(87)80003-3","article-title":"The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination","volume":"15","author":"Levenbook","year":"1987","journal-title":"J Biol Standard"},{"key":"10.1016\/j.vaccine.2016.06.071_b0295","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0264-410X(92)90396-2","article-title":"Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964\u20131988","volume":"10","author":"Nathanson","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1995.tb00090.x","article-title":"Immune defence in mice lacking type I and\/or type II interferon receptors","volume":"148","author":"van den Broek","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2016.06.071_b0310","series-title":"Vesicular stomatitis","author":"Tesh","year":"1975"},{"key":"10.1016\/j.vaccine.2016.06.071_b0315","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.071_b0320","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1128\/JVI.78.20.10920-10926.2004","article-title":"Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus","volume":"78","author":"Coil","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ni.2169","article-title":"Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus","volume":"13","author":"Honke","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0330","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.071_b0335","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0340","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1099\/0022-1317-63-2-493","article-title":"Vesicular stomatitis virus can establish persistent infections in Syrian hamsters","volume":"63","author":"Fultz","year":"1982","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0345","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1073\/pnas.71.8.2956","article-title":"Persistent noncytocidal vesicular stomatitis virus infections mediated by defective T particles that suppress virion transcriptase","volume":"71","author":"Holland","year":"1974","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.071_b0350","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1099\/0022-1317-33-2-193","article-title":"Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro","volume":"33","author":"Holland","year":"1976","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0355","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4269\/ajtmh.1983.32.621","article-title":"Growth and transovarial transmission of Chandipura virus (Rhabdoviridae: Vesiculovirus) in phlebotomus papatasi","volume":"32","author":"Tesh","year":"1983","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2016.06.071_b0360","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/oxfordjournals.aje.a120738","article-title":"The epizootiology of the vesicular stomatitis viruses: a reappraisal","volume":"86","author":"Jonkers","year":"1967","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0365","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.287.5452.485","article-title":"Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice","volume":"287","author":"Mead","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.06.071_b0370","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/oxfordjournals.aje.a121130","article-title":"Ecologic studies of vesicular stomatitis virus. II. Results of experimental infection in Panamanian wild animals","volume":"91","author":"Tesh","year":"1970","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0375","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4269\/ajtmh.1987.36.653","article-title":"Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia","volume":"36","author":"Tesh","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.06.071_b0380","doi-asserted-by":"crossref","first-page":"e1002712","DOI":"10.1371\/journal.ppat.1002712","article-title":"Interferon-induced Ifit2\/ISG54 protects mice from lethal VSV neuropathogenesis","volume":"8","author":"Fensterl","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.06.071_b0385","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3390\/v2122594","article-title":"Insights into arbovirus evolution and adaptation from experimental studies","volume":"2","author":"Ciota","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.06.071_b0390","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vetmic.2012.08.023","article-title":"Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus","volume":"162","author":"Zimmer","year":"2013","journal-title":"Vet Microbiol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.06.071_b0395","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/infdis\/jiv126","article-title":"A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs","volume":"212","author":"Mire","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b0400","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.1128\/JVI.74.23.10903-10910.2000","article-title":"Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1","volume":"74","author":"Rose","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0405","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","article-title":"Recombinant vesicular stomatitis viruses from DNA","volume":"92","author":"Lawson","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.071_b0410","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1073\/pnas.92.18.8388","article-title":"Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones","volume":"92","author":"Whelan","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.071_b0415","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.78.8.3930-3940.2004","article-title":"Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.06.071_b0425","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/viro.1998.9535","article-title":"Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion","volume":"254","author":"Kahn","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.071_b0430","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1128\/JVI.75.22.11079-11087.2001","article-title":"Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge","volume":"75","author":"Kahn","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0435","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virol.2005.06.016","article-title":"Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine","volume":"340","author":"Kapadia","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.071_b0440","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1128\/JVI.76.17.8900-8909.2002","article-title":"Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease","volume":"76","author":"Reuter","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0445","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.071_b0450","article-title":"A recombinant vesicular stomatitis virus ebola vaccine - preliminary report","author":"Regules","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.071_b9000","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.071_b9005","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.071_b0455","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T16:49:35Z","timestamp":1600879775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":93,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16305485"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}